Диссертация (1139475), страница 34
Текст из файла (страница 34)
press, 1957.319. Duraisamy, K. et al. Does Alcohol consumption during multidrugresistanttuberculosis treatment affect outcome? A populationbasedstudy inKerala, India. Ann Am Thorac Soc. 11, 712–718 (2014).320. Eker B. et al. Multidrug- and extensively drug-resistant tuberculosis,Germany. Emerg Infect Dis. 14, 1700–1706 (2008).321. Elliott E., Draper H., Baitsiwe P. & Claassens M. Factors affecting treatmentoutcomes in drug-resistant tuberculosis cases in theNorthern Cape, SouthAfrica. Public Health Action. 4, 201–203 (2014).233322.Eltringham I.J., Drobniewski F. Multiple drug resistant tuberculosis:aetiology, diagnosis and outcome // Br.
Med. Bull. - 1998. - Vol. 54. - № 3. P. 569-578.323. Espinal M.A. The global situation of MDR-TB // Tuberculosis (Edinb).-2003. - Vol. 83. - № 1-3. - P. 44-51.324. Farley J. E. et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB)among a cohort of South African patients with high HIVprevalence. PLoS ONEElectron Resour. 6, e20436, https://doi.org/10.1371/journal.pone.0020436(2011).325. Fleming A. On the antibacterial action of cultures of a penicillium, withspecial reference to their use in the isolation of B. influenza // British Journal ofExperimental Pathology.
– 1929. - Vol.10. - №3. – Р. 226–236.326. Forlanini C. Deutsche Medizinsche Wocheschrifs, 1906. Tuberculosis 1934;16:121.327. Fox W. Studies on the treatment of tuberculosis undertaken by the BritishMedical Research Council Tuberculosis Units, 1946–1986, with relevantsubsequent publications / W. Fox, G.A. Ellard, D.A. Mitchison // J. Tuberc.Lung Dis.
– 1999. – Vol. 2. – Р.231-279.328. Francesc Coll, Jody Phelan, Grant A. Hill-Cawthorne et al. Genome-wideanalysis of multi- and extensivelydrug-resistant Mycobacterium tuberculosis. J.Nature Genetics. 2018, https://doi.org/10.1038/s41588-017-0029-0.329. Franke M. F. et al. Risk factors and mortality associated with default frommultidrug-resistant tuberculosis treatment. Clin InfectDis. 46, 1844–1851(2008).330. Freixinet J. G., Rivas J.J., Rodriguez D., Castro F. et al.
Role of surgery inpulmonary tuberculosis // Med. Sci. Monit. – 2002. - Vol. 8. - №12. – Р.782786.331. Freixinet J.Surgical indications for treatment of pulmonary tuberculosis //World. J. Surg. – 1997. - Vol. 21. - №5. Р. 475-479.234332. Frieden T. K. A multi-institutional outbreak of highly drug-resistanttuberculosis. Epidemiology and clinical out comes / T.K. Frieden, L.F.Sherman, K.L.
Maw et al. // JAMA. – 1996. – N. 276. – P. 1229-35.333. Friedman et al. Negative impact of antibiotic resistance // ClinicalMicrobiology and Infection. - 2016. - Vol.22. - №5. – P.416-422.334. Galie N., Marica C., Posea R., Tabacu E. Current indications of surgicaltreatment in lung tuberculosis // Pneumologia. – 2003. - Vol.52. - №1. – Р. 6568.335.
Gandhi N. R. et al. Risk factors for mortality among MDR- and XDR-TBpatients in a high HIV prevalence setting. Int J Tuberc LungDis. 16, 90–97(2012).336. Gegia M., Kalandadze, I., Kempker, R. R., Magee, M. J. & Blumberg, H.M.Adjunctive surgery improves treatment outcomes amongpatients withmultidrug-resistant and extensively drug-resistant tuberculosis. J Infect Dis.
16,391–396 (2012).337. Gholami K. Evaluation of anti-tuberculosis induced adverse reactions inhospitalized patients / K. Gholami, E. Kamali, M. Hajiabdolbaghi, G. Shalviri //Pharmacy Practice. – 2006. – Vol.4. – №3. – Р.134–138.338. Gilchrist Ebenezer. The Use of Sea Voyage in Medicine and Particularly in aComsumption with Observations on that Disease. T.
Cadell, in the Strand,London, 1771, 308p.339. Gimferrer J.M., Mestres C.A. // Role of surgery in drug-resistant pulmonarytuberculosis. - Asian Cardiovasc Thorac Ann.- 2005. - Vol.13. - №3. – Р. 201202.340. Gler M. T. et al. Weight gain and response to treatment for multidrugresistant tuberculosis. J Trop Med. 89, 943–949 (2013).341. Gninafon M.
Formation du personnel dans le cadre du Programme NationalContre la Tuberculosis // Abstr. 30th IUATLD World Conf. lung Health,Madrid, 14-18 Sept., 1999 // Int. J. Tuberc. Lung Disease. – 1999. – Vol. 3, №9, Suppl. 1. – P.11-12.235342. Gulbay B. E. Side effects due to primary antituberculosis drugs during theinitial phase of therapy in 1149 hospitalized patients for tuberculosis / B. E.Gulbay, O. U. Gurkan, O. A. Yildiz, Z. P. Onen, F. O.
Erkekol, A. Baççioğlu,T. Acican // Respir Med. – 2006. – Vol. 100. – P. 1834–42.343. Hartkoorn RC, Uplekar S, Cole ST Cross-resistance between clofazimineand bedaquiline through upregulation of MmpL5 in Mycobacteriumtuberculosis // Antimicrob Agents Chemother. – 2014. – Vol. 58. – P. 2979–2981.344. Hastings J, Storks R. A case of tuberculosis excavation of the left lungtreated by perforation of the cavity through the walls of the chest. London:Wilson and Ogilvy, 1844.345. Hawkins, J. Antibacterial susceptibility tests: mycobacteria / J. Hawkins, R.Wallace, B. Brown // In.: Manual of clinical microbiology (ed.
A.Balows et al.),Washington. – 1991. – Р. 1138-1152.346. Heifets L., Lindholm-Levy P. Comparison of bactericidal activities ofstreptomycin, amikacin, kanamycin, and capreomycin against Mycobacteriumavium and M. tuberculosis // Antimicrobial Agents and Chemotherapy. – 1989.– Vol. 33. - №8. – P. 1298-1301.347.
Herr J. et al. Cyclic peptide antibiotic similar to viomycine, produced byStreptomyces capreolus NRLL 2773 // 140th Am. Chem. Soc. Meet. Abstractsof papers. Chicago, Sept. 1961. – P 49C.348. Hicks R. M. et al. Malnutrition associated with unfavorable outcome anddeath among South African MDR-TB and HIV coinfectedchildren. J Tuberc.18, 1074–1083 (2014).349. Hirano K, Takahashi M, Kazumi Y, et al. Mutation in pncA is a majormechanism of pyrazinamide resistance in Mycobacterium tuberculosis //Tubercle and Lung Disease: the Official Journal of the International UnionAgainst Tuberculosis and Lung Disease.
– 1997. Vol. 78. - № 2. – P. 117 – 122.236350. Hutchisoii D.C.S., Drobniewski F.A., Milburn H.J. Management ofmultiple drug-resistant tuberculosis // Respiratory Medicine. - 2003. - Vol. 97. № 1.-P. 65-70.351. IsemanM.D.Treatmentandimplicationsof multidnug-resistanttuberculosis for the 21st centtury // Chemotherapy. - 1999. - № 45. - Suppl. 2.
–P. 34-35.352. IsemanM.D.Managementofmultidrug-resistanttuberculosis//Chemotherapy. - 1999. - Vol.45. - Suppl. 2. - P.3-11.353. Iseman MD. Treatment of multidrug-resistant tuberculosis // N Engl J Med1993; 329:784–91.354. Islam M.M., Hameed H.M., Mugweru J. et al. Drug resistance mechanismsand novel drug targets for tuberculosis therapy. J Genet Genomics. 2017, 44(1):рр. 21-37.355.
Jacobeus H.C. Endopleurale operationen unter der leitung des thorakoskops.Beitr Klin Tuberk Spezif Tuberkuloseforsch 1915; 35:1–35.356. Jacobeus HC. The cauterization of adhesions in artificial neumothoraxtherapy of pulmonary tuberculosis. Am Rev Tuberc 1922; 6: 871–97.357. Jacobeus HC. The practical importance of thoracoscopy in surgery of thechest. Surg Gynecol Obstet1922; 34:289 – 96.358. Jacoby G. New mechanisms of bacterial resistance to antimicrobial agents /G.Jacoby, G. Archer // N. Engl.
J. Med. – 1991. – Vol. 324. – P. 601-612.359. Jain K., Desai, M., Solanki, R. & Dikshit, R. K. Treatment outcome ofstandardized regimen in patients with multidrug resistanttuberculosis. JPharmacol Pharmacother. 5, 145–149 (2014).360. James Carson, 1820. In: Moriston Davies, Pulmonary Tuberculosis. Medicaland Surgical Treatment, London, 1933.361. Javadi M. R. Adverse reactions of anti-tuberculosis drugs in hospitalizedpatients: incidence, severity and risk factors / M.R.
Javadi, G. Shalviri, K.Gholami, J. Salamzadeh, G. Maghooli, S.M. Mirsaeedi // PharmacoepidemiolDrug Saf. – 2007. – Vol.16. – №10. – P. 1104–10.237362. Jeon D. S. et al. Survival and predictors of outcomes in non-HIV-infectedpatients with extensively drug-resistant tuberculosis. JTuberc. 13, 594–600(2009).363. Jereb E.A. Nosocomial outbreak of tuberculosis in a renal transplant unit:application of a new technique for restriction fragment length polymorphismanalysis of Mycobacterium tuberculosis isolates / E.A.
Jereb, D.R. Burwen,S.W. Dooley et al. // J. Infect. Dis. – 1993. – N. 168. – P. 1219-1224364. Kang MW, Kim HK, Choi YS, et al. Surgical treatment for multidrugresistant and extensive drug-resistant tuberculosis. Ann Thorac Surg 2010; 89:1597–602.365. KempkerR.R.etal.AcquiredDrugResistanceinMycobacteriumtuberculosis and Poor Outcomes among Patients withMultidrug-Resistant Tuberculosis. Emerg Infect Dis. 21, 992–1001 (2015).366. Кhaliaukin A. et al. Poor treatment outcomes among multidrug-resistanttuberculosis patients in Gomel Region, Republic ofBelarus. Public HealthAction. 4, S24–S28 (2014).367.
Kim H.J., Kang C.H., Kim Y.T. et al. // Eur Respir J. – 2006. – Vol. -28. № 3. – Р. 576-580.368. Kir A., Inci I., Torun T., Atasalihi A., Tahaoglu K. Adjuvant resectionalsurgery improves cure rates in multidrug-resistant tuberculosis // J. Thorac.Cardiovasc. Surg. - 2006 . - Vol. 131. – Р. 693-696.369. Kir A., Tahaoglu K., Okur E., Hatipoglu T. Role of surgery in multi-drugresistant tuberculosis: results of 27 cases // Eur. J.
Cardiothorac. Surg. – 1997. Vol. -12. - №4. – Р. 531-534.370. Koch A., Mizrahi V. and Warner D.F. The impact of drug resistance onMycobacterium tuberculosis physiology: what can we learn from rifampicin? //EmergingMicrobesandInfections.–2014.–Vol.3.-e17.;https://www.nature.com/articles/emi201417.371. Krüüner Annika, Jureen Pontus, Levina Klavdia, Ghebremichael Solomon,Hoffner Sven.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
